natgillin/translations-raw huggingface dataset:
Manufacturer Penn Pharmaceutical Services Limited Tafarnaubach Industrial Estate Tredegar Gwent NP22 3AA United Kingdom
Izdelovalec Penn Pharmaceutical Services Limited Tafarnaubach Industrial Estate Tredegar Gwent NP22 3AA Velika Britanija
Reyataz is a medicine that contains the active substance atazanavir.
Reyataz je zdravilo, ki vsebuje zdravilno učinkovino atazanavir.
It is available as capsules (blue and white:
Na voljo je v obliki kapsul (modre in bele:
100 mg; light blue and blue:
100 mg; svetlo modre in modre:
150 mg; opaque blue:
150 mg; neprozorne modre:
200 mg; red and blue:
200 mg; rdeče in modre:
300 mg) and as an oral powder (50 mg per 1.5 g measure).
300 mg) ter v obliki peroralnega praška (50 mg v 1, 5 gramske merice).
Reyataz is an antiviral medicine.
Zdravilo Reyataz je protivirusno zdravilo.
It is used together with ritonavir (another antiviral medicine) and other antiviral medicines to treat adults infected with human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS).
Uporablja se skupaj z ritonavirjem (drugim protivirusnim zdravilom) in drugimi protivirusnimi zdravili pri zdravljenju odraslih, ki so okuženi z virusom humane imunske pomanjkljivosti tipa 1 (HIV- 1), virusom, ki povzroča sindrom pridobljene imunske pomanjkljivosti (AIDS).
Doctors should prescribe Reyataz to patients who have received antiviral medicines for HIV infection before only once they have looked at these medicines and the likelihood that the virus will respond to Reyataz.
Zdravniki lahko zdravilo Reyataz predpišejo le bolnikom, ki so že jemali protivirusna zdravila za zdravljenje okužbe s HIV, ko se seznanijo s temi zdravili in verjetnostjo, da se bo virus odzval na zdravilo Reyataz.
Based on the information available, the medicine is not expected to work in patients in whom many medicines in the same class as Reyataz (protease inhibitors) do not work or have stopped working.
Na podlagi razpoložljivih informacij ni pričakovati, da bi zdravilo učinkovalo pri bolnikih, pri katerih številna zdravila iz istega razreda kot zdravilo Reyataz (zaviralci proteaze) ne učinkujejo ali so prenehala učinkovati.
Treatment with Reyataz should be started by a doctor who has experience in the treatment of HIV infection.
Zdravljenje z zdravilom Reyataz mora začeti zdravnik, ki ima izkušnje z zdravljenjem okužbe s HIV.
The recommended dose is 300 mg once a day.
Priporočeni odmerek znaša 300 mg enkrat dnevno.
Each dose must be taken with 100 mg ritonavir and food.
Vsak odmerek je treba vzeti s 100 mg ritonavirja in hrano.
The oral powder can be used in patients who are unable to swallow capsules.
Peroralni prašek se lahko uporablja pri bolnikih, ki ne morejo pogoltniti kapsul.
Reyataz should be used with caution in patients with mild liver problems, and should not be used in patients with moderate or severe liver problems.
Zdravilo Reyataz je treba pri bolnikih z blagimi težavami z jetri uporabljati previdno, ne sme pa se uporabljati pri bolnikih z zmernimi ali resnimi težavami z jetri.
It slows down the rate at which atazanavir is broken down, increasing the levels of atazanavir in the blood.
Ta upočasnjuje stopnjo razgradnje atazanavirja in povečuje ravni atazanavirja v krvi.
This allows a lower dose of atazanavir to be used for the same antiviral effect.
To omogoča, da za dosego enakega protivirusnega učinka zadošča uporaba manjšega odmerka atazanavirja.
Reyataz does not cure HIV infection or AIDS, but it may
Zdravilo Reyataz, če ga jemljemo v kombinaciji z drugimi protivirusnimi zdravili, zmanjša količino virusa HIV v krvi in ga ohranja na nizki ravni.
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
Zdravilo 7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
Reproduction is authorised provided the source is acknowledged. delay the damage to the immune system and the development of infections and diseases associated with AIDS.
Reyataz ne ozdravi okužbe s HIV ali AIDS- a, vendar pa lahko upočasni slabšanje imunskega sistema ter razvoj okužb in bolezni, povezanih z AIDS- om.
The effectiveness of Reyataz has been assessed in four main studies.
Učinkovitost zdravila Reyataz so proučevali v štirih glavnih študijah.
One study involved 883 treatment-naïve patients (who had not taken treatment for HIV infection before), and the other three involved a total of 743 treatment-experienced patients (who had taken treatment for HIV infection before).
V eno študijo je bilo vključenih 883 bolnikov (ki prej še niso bili zdravljeni zaradi okužbe s HIV), v druge tri študije pa je bilo skupno vključenih 743 predhodno zdravljenih bolnikov (ki so že prejemali zdravila proti okužbi s HIV).
In the study of treatment-naïve patients, the effectiveness of Reyataz was compared with that of lopinavir (another antiviral medicine), both taken with ritonavir.
V študiji s predhodno nezdravljenimi bolniki so učinkovitost zdravila Reyataz primerjali z učinkovitostjo lopinavirja (drugega protivirusnega zdravila), pri čemer sta se oba uporabila v kombinaciji z ritonavirjem.
In treatment-experienced patients, the first two studies compared the effectiveness of Reyataz, taken with saquinavir (another antiviral medicine) but without ritonavir, with that of the combination of ritonavir and either saquinavir or lopinavir.
Pri zdravljenju predhodno zdravljenih bolnikov so v prvih dveh študijah primerjali učinkovitost zdravila Reyataz v kombinaciji s sakvinavirjem (drugim protivirusnim zdravilom), vendar brez ritonavirja, z učinkovitostjo kombinacije ritonavirja in sakvinavirja oziroma lopinavirja.
The third study compared the effectiveness of Reyataz plus either ritonavir or saquinavir with that of lopinavir plus ritonavir in 358 patients.
V tretji študiji so pri 358 bolnikih primerjali učinkovitost zdravila Reyataz v kombinaciji z ritonavirjem oziroma sakvinavirjem, z učinkovitostjo lopinavirja v kombinaciji z ritonavirjem.
In all of the studies, the patients also took two nucleoside or nucleotide reverse transcriptase inhibitors (NRTIs, a type of antiviral medicine).
V vseh študijah so bolniki prejemali tudi dva nukleozidna ali nukleotidna zaviralca reverzne transkriptaze (NRTI, vrsto protivirusnega zdravila).
The main measure of effectiveness was the change in the levels of HIV in the patients’ blood (viral load).
Glavno merilo učinkovitosti je bila sprememba koncentracije virusa HIV (virusnega bremena) v krvi bolnika.
In treatment-naïve patients, Reyataz was as effective as lopinavir, when they were taken with ritonavir.
Pri zdravljenju bolnikov, ki predhodno še niso bili zdravljeni, je bilo zdravilo Reyataz enako učinkovito kot lopinavir, kadar se je jemal skupaj z ritonavirjem.
At the start of the study, the patients’ viral loads were around 88,100 copies/ ml, but after 48 weeks, 78% of the patients taking Reyataz (343 out of 440) had viral loads below 50 copies/ ml, compared with 76% of those taking lopinavir (338 out of 443).
Na začetku študije je bilo virusno breme pri bolnikih okoli 88, 100 kopij/ ml, vendar pa je bilo po 48 tednih virusno breme pri 78% bolnikov, ki so jemali zdravilo Reyataz (343 od 440) nižje od 50 kopij/ ml v primerjavi s 76% tistih, ki so jemali lopinavir (338 od 443).
In treatment-experienced patients, the results of the first study could not be interpreted, as a large number of patients left the study before its planned end.
Pri zdravljenju predhodno zdravljenih bolnikov rezultatov prve študije ni bilo mogoče razložiti, ker je veliko število bolnikov prekinilo sodelovanje v študiji še pred načrtovanim zaključkom.
In the second study, the combination of lopinavir and ritonavir caused a greater reduction in viral load than Reyataz taken without ritonavir after 24 weeks.
V drugi študiji je kombinacija lopinavirja in ritonavirja povzročila večje zmanjšanje virusnega bremena po 24 tednih kot zdravilo Reyataz brez ritonavirja.
In the third study, patients taking Reyataz or lopinavir, in combination with ritonavir, had similar falls in viral load after 24 and 48 weeks, having fallen by around 99% after 48 weeks.
V tretji študiji je bilo pri bolnikih, ki so jemali zdravilo Reyataz oziroma lopinavir v kombinaciji z ritonavirjem, ugotovljeno podobno zmanjšanje virusnega bremena po 24 in 48 tednih, pri čemer je bilo zmanjšanje po 48 tednih približno 99- odstotno.
The most common side effects with Reyataz (seen in between 1 and 10 patients in 100) are headache, ocular icterus (yellowing of the eyes), vomiting, diarrhoea, abdominal (tummy) pain, nausea (feeling sick), dyspepsia (heartburn), rash, lipodystrophy syndrome (changes in the distribution of body fat), fatigue (tiredness) and jaundice (yellowing of the skin).
Najpogostejši neželeni učinki zdravila Reyataz (opaženi pri 1 do 10 bolnikih izmed 100) so glavobol, očesni ikterus (rumeno obarvanje oči), bruhanje, driska, bolečine v trebuhu, navzeja (občutek slabosti), dispepsija (zgaga), izpuščaji, sindrom lipodistrofije (spremembe v porazdelitvi maščobe v telesu), utrujenost in zlatenica (porumenitev kože).
For the full list of all side effects reported with Reyataz, see the Package Leaflet.
Za celoten seznam vseh neželenih stranskih učinkov, o katerih so poročali pri uporabi zdravila Reyataz, glejte navodilo za uporabo.
Reyataz should not be used in people who may be hypersensitive (allergic) to atazanavir or any of the other ingredients, or who have moderate to severe problems with their liver.
Zdravila Reyataz ne smejo uporabljati osebe, ki utegnejo biti preobčutljive za (alergične na) atazanavir ali katero koli drugo sestavino zdravila ali ki imajo zmerne do hude težave z jetri.
Reyataz must not be used in patients taking any of the following medicines: • rifampicin (used to treat tuberculosis); • St John’ s wort (a herbal preparation used to treat depression); • medicines that are broken down in the same way as Reyataz or ritonavir and are harmful at high levels in the blood.
Zdravila Reyataz ne smejo jemati bolniki, ki jemljejo katero od naslednjih zdravil: • rifampicin (zdravilo za zdravljenje tuberkuloze), • šentjanževko (rastlinski pripravek, ki se uporablja za zdravljenje depresije), • zdravila, ki se presnavljajo enako kot zdravilo Reyataz ali ritonavir ter so pri visokih ravneh v krvi škodljiva.
Caution is needed when Reyataz is taken at the same time as other medicines.
Pri sočasnem jemanju zdravila z drugimi zdravili je potrebna previdnost.
As with other anti-HIV medicines, patients taking Reyataz may also be at risk of osteonecrosis (death of bone tissue) or immune reactivation syndrome (symptoms of infection caused by the recovering immune system).
Enako kot pri drugih zdravilih proti virusu HIV obstaja pri bolnikih, ki jemljejo zdravilo Reyataz, tveganje za osteonekrozo (odmiranje kostnega tkiva) ali sindrom imunske reaktivacije (simptome okužbe, ki jih povzroči imunski sistem med okrevanjem).
Patients who have problems with their liver may be at an elevated risk of liver damage when taking Reyataz.
Pri bolnikih, ki imajo težave z jetri, obstaja pri jemanju zdravila Reyataz povečano tveganje za okvare jeter.
The Committee for Medicinal Products for Human Use (CHMP) decided that Reyataz’ s benefits are greater than its risks for the treatment of HIV-1 infected adults in combination with other antiretroviral medicinal products.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Reyataz za zdravljenje odraslih, okuženih s HIV- 1, v kombinaciji z drugimi protiretrovirusnimi zdravili, večje
The Committee recommended that Reyataz be given marketing authorisation.
Odbor je priporočil, da se za zdravilo Reyataz odobri dovoljenje za promet.
Reyataz was originally authorised under ‘ Exceptional Circumstances’, because for scientific reasons it had not been possible to obtain complete information on the medicine.
Zdravilo Reyataz je bilo odobreno v „ izjemnih okoliščinah “, ker zaradi znanstvenih razlogov ni bilo mogoče pridobiti vseh informacij o njem.
As the company had supplied the additional information requested, the ‘ Exceptional Circumstances ’ ended on 25 July 2008.
Ker je družba predložila dodatne zahtevane podatke, so „ izjemne okoliščine “ prenehale veljati 25. julija 2008.
2/ 3 Other information about Reyataz:
Druge informacije o zdravilu Reyataz:
The European Commission granted a marketing authorisation valid throughout the European Union for Reyataz to Bristol-Myers Squibb Pharma EEIG on 2 March 2004.
Evropska komisija je dovoljenje za promet z zdravilom Reyataz, veljavno po vsej Evropski uniji, odobrila družbi Bristol- Myers Squibb Pharma EEIG dne 2. marca 2004.
The marketing authorisation was renewed on 2 March 2009.
Dovoljenje za promet z zdravilom je bilo obnovljeno 2. marca 2009.
The full EPAR for Reyataz can be found here.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Reyataz je na voljo tukaj.
Invented name
izmišljeno ime
Capsule, hard Capsule, hard Capsule, hard Capsule, hard Capsule, hard Capsule, hard
kapsula, trda kapsula, trda kapsula, trda kapsula, trda kapsula, trda kapsula, trda
Oral use Oral use Oral use Oral use Oral use Oral use
peroralna uporaba peroralna uporaba peroralna uporaba peroralna uporaba peroralna uporaba peroralna uporaba
bottle (HDPE) blister (alu/ alu) bottle (HDPE) blister (alu/ alu) bottle (HDPE) blister (alu/ alu)
plastenka (HDPE) pretisni omot (alu/ alu) plastenka (HDPE) pretisni omot (alu/ alu) plastenka (HDPE) pretisni omot (alu/ alu)
60 capsules 60 capsules 60 capsules 60 capsules 60 capsules 60 capsules
60 kapsul 60 kapsul 60 kapsul 60 kapsul 60 kapsul 60 kapsul
50 mg/ 1.5 g 300 mg 300 mg 300 mg
50 mg/ 1, 5 g 300 mg 300 mg 300 mg
Oral powder Capsule, hard Capsule, hard Capsule, hard
peroralni prašek kapsula, trda kapsula, trda kapsula, trda
bottle (HDPE) bottle (HDPE) blister (alu/ alu) 3 bottles (HDPE)
plastenka (HDPE) plastenka (HDPE) pretisni omot (alu/ alu) 3 plastenke (HDPE)
1 bottle 30 capsules 30 capsules 30 capsules
1 plastenka 30 kapsul 30 kapsul 30 kapsul
Each capsule contains 100 mg of atazanavir (as sulphate)
Ena kapsula vsebuje 100 mg atazanavirja (v obliki sulfata).
54.79 mg of lactose per capsule.
54, 79 mg laktoze na kapsulo
Hard capsule Opaque blue and white capsule printed with white and blue inks, with "BMS 100 mg" on one half and with "3623" on the other half.
Oznaki sta bele in modre barve.
REYATAZ is indicated for the treatment of HIV-1 infected adults in combination with other antiretroviral medicinal products.
Zdravilo REYATAZ je indicirano za zdravljenje s HIV- 1 okuženih odraslih v kombinaciji z drugimi protiretrovirusnimi zdravili.
In antiretroviral treatment experienced patients, the demonstration of efficacy is based on a study comparing REYATAZ 300 mg once daily in combination with ritonavir 100 mg once daily with lopinavir/ ritonavir, each regimen in combination with tenofovir (see sections 4.8 and 5.1).
Pri bolnikih, predhodno zdravljenih s protiretrovirusnimi zdravili, temelji dokaz učinkovitosti in varnosti na študiji, ki je primerjala uporabo zdravila REYATAZ 300 mg enkrat na dan v kombinaciji z ritonavirjem 100 mg enkrat na dan z uporabo lopinavirja/ ritonavirja, obe shemi v kombinaciji s tenofovirjem (glejte poglavji 4. 8 in 5. 1).
Based on available virological and clinical data, no benefit is expected in patients with strains resistant to multiple protease inhibitors (≥ 4 PI mutations).
Glede na razpoložljive virološke in klinične podatke ni pričakovati koristi pri bolnikih s sevi, odpornimi proti več zaviralcem proteaz (≥ 4 mutacije zaviralcev proteaz).
The choice of REYATAZ in treatment experienced patients should be based on individual viral resistance testing and the patient’ s treatment history (see section 5.1).
Pri predhodno že zdravljenih bolnikih mora izbira zdravila REYATAZ temeljiti na individualnem testiranju virusne odpornosti in na anamnezi bolnikovega zdravljenja (glejte poglavje 5. 1).
Adults: the recommended dose of REYATAZ is 300 mg once daily taken with ritonavir 100 mg once daily and with food.
Odrasli: priporočeni odmerek zdravila REYATAZ je 300 mg enkrat na dan skupaj z ritonavirjem v odmerku 100 mg enkrat na dan in skupaj s hrano.
Ritonavir is used as a booster of atazanavir pharmacokinetics (see sections 4.5 and 5.1).
Ritonavir se uporablja kot stopnjevalec farmakokinetike atazanavirja (glejte poglavji 4. 5 in 5. 1).
If REYATAZ with ritonavir is co-administered with didanosine, it is recommended that didanosine be taken 2 hours after REYATAZ with ritonavir.
Če bolnik zdravilo REYATAZ z ritonavirjem jemlje skupaj z didanozinom, je priporočljivo, da didanozin vzame 2 uri po zdravilu REYATAZ z ritonavirjem.
REYATAZ with ritonavir must be taken with food (see section 4.5).
Zdravilo REYATAZ z ritonavirjem je treba jemati skupaj s hrano (glejte poglavje 4. 5).
Infants, toddlers, children, and adolescents: the safety and efficacy of REYATAZ in paediatric patients has not been established (see section 5.2).
Dojenčki, malčki, otroci in mladostniki: pri otrocih varnosti in učinkovitosti zdravila REYATAZ niso dokazali (glejte poglavje 5. 2).
Patients with renal impairment: no dosage adjustment is needed (see section 5.2).
Bolniki z okvaro ledvic: odmerka ni treba prilagajati (glejte poglavje 5. 2).
REYATAZ with ritonavir should be used with caution in patients with mild hepatic impairment.
Pri bolnikih z blago okvaro jeter je treba zdravilo REYATAZ z ritonavirjem uporabljati
REYATAZ should not be used in patients with moderate to severe hepatic impairment (see sections 4.3, 4.4, and 5.2).
Zdravila REYATAZ se ne sme uporabljati pri bolnikih z zmerno do hudo okvaro jeter (glejte poglavja 4. 3, 4. 4 in 5. 2).
2 Method of administration: for oral administration.
Način uporabe: za peroralno uporabo.
REYATAZ oral powder is available for patients who are unable to swallow capsules (see Summary of Product Characteristics for REYATAZ oral powder).
(Glejte povzetek glavnih značilnosti zdravila za peroralni prašek REYATAZ).
Patients with moderate to severe hepatic insufficiency (see sections 4.2 and 4.4).
Bolniki z zmerno do hudo insuficienco jeter (glejte poglavji 4. 2 in 4. 4).
Combination of rifampicin and REYATAZ with concomitant low-dose ritonavir is contraindicated (see section 4.5).
Sočasna uporaba rifampicina in zdravila REYATAZ skupaj z nizkim odmerkom ritonavirja je kontraindicirana (glejte poglavje 4. 5).
REYATAZ with ritonavir must not be used in combination with medicinal products that are substrates of the CYP3A4 isoform of cytochrome P450 and have narrow therapeutic windows (e. g., astemizole, terfenadine, cisapride, pimozide, quinidine, bepridil, triazolam, midazolam administered orally (for caution on parenterally administered midazolam, see section 4.5), and ergot alkaloids, particularly, ergotamine, dihydroergotamine, ergonovine, methylergonovine) (see section 4.5).
Zdravilo REYATAZ z ritonavirjem se ne sme uporabljati v kombinaciji z zdravili, ki so substrati izooblike CYP3A4 citokroma P450 in imajo ozko terapevtsko okno (npr. astemizol, terfenadin, cisaprid, pimozid, kinidin, bepridil, triazolam, peroralne oblike midazolama (za previdnost pri parenteralnih oblikah midazolama glejte poglavje 4. 5) in alkaloidi ergot, zlasti ergotamin, dihidroergotamin, ergonovin, metilergonovin) (glejte poglavje 4. 5).
John’ s wort (Hypericum perforatum) (see section 4.5).
Zdravilo REYATAZ se ne sme uporabljati v kombinaciji s pripravki, ki vsebujejo šentjanževko (Hypericum perforatum) (glejte poglavje 4. 5).
Patients should be advised that current antiretroviral therapy has not been proven to prevent the risk of transmission of HIV to others through blood or sexual contact.
Za trenutne oblike protiretrovirusnega zdravljenja ni bilo dokazano, da bi lahko preprečila tveganje za prenos virusa HIV na druge s krvjo ali spolnimi stiki.
Appropriate precautions should continue to be employed.
Bolnike je treba s tem seznaniti in jih opozoriti, da morajo še naprej upoštevati ustrezne previdnostne ukrepe.
Co-administration of REYATAZ with ritonavir in doses greater than 100 mg once daily has not been clinically evaluated.
Sočasna uporaba zdravila REYATAZ z ritonavirjem v odmerkih, večjih od 100 mg enkrat na dan, ni klinično ovrednotena.
The use of higher ritonavir doses might alter the safety profile of atazanavir (cardiac effects, hyperbilirubinaemia) and therefore is not recommended.
Uporaba večjih odmerkov ritonavirja lahko spremeni varnostni profil atazanavirja (učinki na srce, hiperbilirubinemija) in zato ni priporočljiva.
Patients with coexisting conditions Atazanavir is primarily hepatically metabolised and increased plasma concentrations were observed in patients with hepatic impairment (see sections 4.2 and 4.3).
Bolniki s sočasnimi boleznimi Atazanavir se primarno presnavlja v jetrih in pri bolnikih z okvaro jeter so opažali zvišanje njegove koncentracije v plazmi (glejte poglavji 4. 2 in 4. 3).
The safety and efficacy of REYATAZ has not been established in patients with significant underlying liver disorders.
Varnost in učinkovitost zdravila REYATAZ ni raziskana pri bolnikih s pomembnimi osnovnimi boleznimi jeter.
In case of concomitant antiviral therapy for hepatitis B or C, please refer also to the relevant Summary of Product Characteristics for these medicinal products (see section 4.8).
V primeru sočasnega zdravljenja hepatitisa B ali C je treba upoštevati povzetke glavnih značilnosti za uporabljena zdravila (glejte poglavje 4. 8).
Patients with pre-existing liver dysfunction, including chronic active hepatitis, have an increased frequency of liver function abnormalities during combination antiretroviral therapy and should be monitored according to standard practice.
Pri bolnikih z okvarami jeter, vključno s kroničnim aktivnim hepatitisom, so med kombiniranim protiretrovirusnim zdravljenjem okvare jeter pogostejše, zato jih je treba nadzirati v skladu s standardno prakso.
Dose related asymptomatic prolongations in PR interval with REYATAZ have been observed in clinical studies.
Pri zdravljenju z zdravilom REYATAZ so v kliničnih študijah opazili od odmerka odvisno asimptomatsko podaljšanje intervala PR na EKG.
In patients with pre-existing conduction problems (second degree or higher atrioventricular or complex bundle-branch block), REYATAZ should be used with caution and only if the benefits exceed the risk (see section 5.1).
Pri bolnikih z obstoječimi motnjami prevajanja (atrioventrikularni blok druge ali višje stopnje ali kompleksni kračni blok) je treba zdravilo REYATAZ uporabljati previdno in le, če korist odtehta tveganje (glejte poglavje 5. 1).
Particular caution should be used when prescribing REYATAZ in association with medicinal products which have the potential to increase the QT interval and/ or in patients with pre-existing risk factors (bradycardia, long congenital QT, electrolyte imbalances (see sections 4.8 and 5.3).
Posebna previdnost je potrebna pri predpisovanju zdravila REYATAZ skupaj z zdravili, ki lahko podaljšajo interval QT, in/ ali pri bolnikih z že obstoječimi dejavniki tveganja (bradikardija, prirojeno podaljšanje intervala QT, neravnovesje elektrolitov) (glejte poglavji 4. 8 in 5. 3).
3 There have been reports of increased bleeding, including spontaneous skin haematomas and haemarthroses, in type A and B haemophiliac patients treated with protease inhibitors.
3 Pri bolnikih s hemofilijo A ali B, ki so dobivali zaviralce proteaz, so poročali o pogostejših krvavitvah, vključno s spontanimi kožnimi hematomi in hemartrozami.
Fat redistribution and metabolic disorders Combination antiretroviral therapy has been associated with the redistribution of body fat (lipodystrophy) in HIV patients.
Prerazporeditev maščevja in presnovne motnje Pri bolnikih, okuženih z virusom HIV, je kombinirano protiretrovirusno zdravljenje povezano s prerazporeditvijo telesnega maščevja (lipodistrofijo).
The long-term consequences of these events are currently unknown.
Dolgotrajne posledice teh sprememb za zdaj niso znane.
A connection between visceral lipomatosis and protease inhibitors and lipoatrophy and nucleoside reverse transcriptase inhibitors has been hypothesised.
Domnevno obstaja povezava med visceralno lipomatozo in zaviralci proteaz ter lipoatrofijo in nukleozidnimi zaviralci reverzne transkriptaze.